177Lu-EDTMP is the 177Lu equivalent of 153Sm-Lexidronam (153Sm-EDTM) developed for the same indication of bone pain palliation. This is a cheap way to bypass the IP of Quadramet although by now 153Sm-EDTMP is available as a generic as well. 177Lu-EDTMP is mainly available in countries where 153Sm-Quadramet was not available or too expensive.

177Lu-EDTMP is, like 153Sm-EDTMP, indicated for bone pain palliation in cancer metastases (prostate). IAEA has supported the development of this tracer and sponsored a multicenter clinical trial of 177Lu-EDTMP.

Target/Mechanism: Bones

Leading Emitter: beta electrons (β–)